Transparency Market Research Hospital Infection Therapeutics Market Industry Analysis, Pipeline Analysis, Size, Growth, Trends and Forecast 2014 - 2020
Published Date 01-Sep-2014
121 Page Report
Buy Now
Request Sample
Global Share,
Press Release
Hospital Infection Therapeutics Market Expected to Reach USD 3.62 Billion Globally in 2020
Transparency Market Research State Tower, 90, State Street, Suite 700. Albany, NY 12207 United States www.transparencymarketresearch.com sales@transparencymarketresearch.com
Hospital Infection Therapeutics Market
REPORT DESCRIPTION
Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 According to a new market report published by Transparency Market Research “Hospital Infection Therapeutics Market - Global Industry Analysis, Pipeline Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020� the hospital infection therapeutics market was valued at USD 3.06 billion in 2013 and is expected to grow at a CAGR of 3.1% from 2014 to 2020, to reach an estimated value of USD 3.62 billion in 2020. Hospital infections, commonly known as hospital-acquired infections (HAIs) or nosocomial infections, are referred to infections that develop in patients undergoing treatment in a healthcare setting such as hospitals, nursing homes, outpatient surgery centers, dialysis centers and rehabilitation centers. According to the World Health Organization (WHO), hospital infections are those infections that occur within 48 hours of hospitalization or after 72 hours of discharge from hospitals or within 30 days after treatment. Hospital infections mostly originate in intensive care units (ICUs) of a hospital compared to other divisions. According to the Centers for Disease Control and Prevention (CDC), more than 1.7 million hospital infections from different pathogenic microorganisms combined have been reported in 2011, in the U.S. CDC also estimated that hospital infections accounted for 99,000 deaths in the U.S. in the year 2011. We are currently offering a flat 15% discount on all purchases until end of the March 2015:http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html Major hospital infection therapeutics that are available in the global market has been categorized into three major drug segments, namely, antibacterial, antiviral and antifungal drugs. Some of the major types of hospital infections include hospital-acquired pneumonia, urinary tract infections, gastrointestinal disorders, bloodstream infections, surgical site infections and other hospital infections. Major driving factors for the growth of the hospital infection therapeutics market include increasing prevalence of various hospital infections, aging population, increasing healthcare awareness and demand for improved therapeutic drugs. However, increasing multi-drug resistance that has rendered many drugs obsolete and
Transparency Market Research
2
Hospital Infection Therapeutics Market
increasing number of surveillance and infection control programs, such as, point prevalence survey by ECDC, Europe and HAI prevalence survey by CDC, U.S., may restrain the growth of this market. But, increasing multi-drug resistance and demand for improved infection treatment drugs have induced various drug developers and manufacturers to develop advanced therapeutic drugs. Several drugs that are in their phase III clinical trials will soon be commercialized during the forecast period and will add to the growth of this market in future. Some of the major drugs that are in their late stage clinical trials are Ceftolozane/Tazobactam, Dalvance, Delafloxacin, MK-3415A, Surotomycin, Eravacycline, and Tedizolid among others. North America dominates the global hospital infection therapeutics market, in terms of revenue, followed by the European market in 2013. Major factors responsible for the leading position of the North American market are high prevalence of various hospital infections, rising number of multidrug-resistant microbial pathogens, and increasing demand for advanced therapeutics. High awareness level along with high purchasing capacity of the people is also contributing to the growth of the market in the region. Rising geriatric population in North America and Europe will add to the population of affected patients with hospital infections as aged patients exhibit lowered immunity levels. Thus, the increase in affected patient population will require increased use of various therapeutic drugs, which in turn will contribute towards the growth of this market. Asia-Pacific is expected to show the highest rate of growth in the global hospital infection therapeutics market during the forecast period 2014 to 2020. Some of the major factors responsible for high growth rate are rapidly increasing prevalence of hospital-acquired infections in the region, rising awareness and demand for new and improved hospital infection treatment drugs, and increasing healthcare infrastructure as well as purchasing power of people in the region. Actavis plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi are some of the major players operating in the global hospital infection therapeutics market. Get Sample Report Copy with TOC and Market Research :http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1280 See More Articles :- https://www.linkedin.com/today/author/349336221 The global hospital infection therapeutics market is segmented as follows: Hospital Infection Therapeutics Market, by Drug Type
Transparency Market Research
3
Hospital Infection Therapeutics Market
•
Antibacterial Drugs
•
Antiviral Drugs
•
Antifungal Drugs
Hospital Infection Therapeutics Market, by Major Infections
•
Hospital-Acquired Pneumonia
•
Surgical Site Infections
•
Urinary Tract Infections
•
Gastrointestinal Disorders
•
Bloodstream Infections
•
Other Hospital Infections
Hospital Infection Therapeutics Market, by Geography
•
North America
•
Europe
•
Asia-Pacific
•
Rest of the World (RoW)
Browse Full Press Release of This Report:http://www.transparencymarketresearch.com/pressrelease/hospital-infectiontherapeutics.htm
TABLE OF CONTENT
Chapter 1 Introduction
Transparency Market Research
4
Hospital Infection Therapeutics Market
1.1 Report Description 1.2 Market Segmentation 1.3 Research Methodology 1.4 Assumptions Chapter 2 Executive Summary 2.1 Market Snapshot: Global Hospital Infection Therapeutics Market 2.2 Comparative Analysis: Global Hospital Infection Therapeutics Market, by Geography, 2013 & 2020 (Value %) Chapter 3 Hospital Infection Therapeutics Market Overview 3.1 Introduction 3.2 Event Impact Analysis 3.3 Market Drivers 3.3.1 High Prevalence of Various Hospital Infections Driving the Demand for Anti-infective Drugs 3.3.2 High Susceptibility of Neonatal Population in a Healthcare Setting Giving Rise to Different Hospital Infections 3.3.3 Lack of Skilled Nursing Staff in Developing and Underdeveloped Economies is Increasing the Prevalence of HAIs 3.4 Market Restraints 3.4.1 Increasing Hospital Surveillance and Infection Control Programs in Developed Countries Leading to a Decline in Number of Hospital Infections 3.4.2 Increasing Number of Multi-drug resistant Bacterial Strains making Presently Available Antibacterial Drugs Obsolete 3.5 Market Opportunities
Transparency Market Research
5
Hospital Infection Therapeutics Market
3.5.1 High Number of Pipeline Drug Molecules for Specific Treatment of HAIs 3.5.2 Increasing Incidences of Hospital Infections and High Unmet Needs in Low to Medium Income Countries of the World 3.6 Value Chain Analysis 3.7 Porter’s Five Forces Analysis: Global Hospital Infection Therapeutics Market 3.7.1 Bargaining Power of Suppliers 3.7.2 Bargaining Power of Buyers 3.7.3 Threat of Substitutes 3.7.4 Threat of New Entrants 3.7.5 Competitive Rivalry 3.8 Market Attractiveness Analysis: Global Hospital Infection Therapeutics Market, by Geography 3.9 Competitive Landscape 3.9.1 Market Share Analysis by Key Players: Hospital Infection Therapeutics Market, 2013 (Value %) Chapter 4 Hospital Infection Therapeutics Market, by Drug Type 4.1 Overview 4.1.1 Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2012 – 2020 (USD Million) 4.1.2 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Drug Type, 2013 & 2020 (Value %) 4.2 Antibacterial Drugs 4.2.1 Global Antibacterial Drugs in HIT Market Revenue, 2012 – 2020 (USD Million) 4.3 Antiviral Drugs
Transparency Market Research
6
Hospital Infection Therapeutics Market
4.3.1 Global Antiviral Drugs in HIT Market Revenue, 2012 – 2020 (USD Million) 4.4 Antifungal Drugs 4.4.1 Global Antifungal Drugs in HIT Market Revenue, 2012 – 2020 (USD Million) 4.5 Pipeline Analysis: Market Forecast 4.5.1 Amikacin Inhale 4.5.1.1 Global Amikacin Inhale Market Revenue (Expected), 2016 – 2020 (USD Million) 4.5.2 CAZ AVI (Ceftazidime/avibactum) 4.5.2.1 Global CAZ AVI Market Revenue (Expected), 2015 – 2020 (USD Million) 4.5.3 Ceftolozane/Tazobactam 4.5.3.1 Global Ceftolozane/tazobactam Market Revenue (Expected), 2015 – 2020 (USD Million) 4.5.4 Dalvance (dalbavancin) 4.5.4.1 Global Dalvance (dalbavancin) Market Revenue (Expected), 2016 – 2020 (USD Million) 4.5.5 Delafloxacin (RX-3341) 4.5.5.1 Global Delafloxacin Market Revenue (Expected), 2015 – 2020 (USD Million) 4.5.6 Eravacycline (TP-434) 4.5.6.1 Global Eravacycline Market Revenue (Expected), 2017 – 2020 (USD Million) 4.5.7 MK-3415A 4.5.7.1 Global MK-3415A Market Revenue (Expected), 2016 – 2020 (USD Million) 4.5.8 Oritavancin 4.5.8.1 Global Oritavancin Market Revenue (Expected), 2017 – 2020 (USD Million) 4.5.9 Plazomicin
Transparency Market Research
7
Hospital Infection Therapeutics Market
4.5.9.1 Global Plazomicin Market Revenue (Expected), 2017 – 2020 (USD Million) 4.5.10 Surotomycin (CB-315) 4.5.10.1 Global Surotomycin Market Revenue (Expected), 2017 – 2020 (USD Million) 4.5.11 Tedizolid (TR-701) 4.5.11.1 Global Tedizolid Market Revenue (Expected), 2015 – 2020 (USD Million) Chapter 5 Hospital Infection Therapeutics Market, by Major Infections 5.1 Overview 5.1.1 Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2012 – 2020 (USD Million) 5.1.2 Comparative Analysis: Global Hospital Infection Therapeutics Market Revenue, by Major Infections, 2013 & 2020 (Value %) 5.2 Hospital-Acquired Pneumonia (HAP) 5.2.1 Global HAP Therapeutics Market Revenue, 2012 – 2020 (USD Million) 5.3 Surgical Site Infections (SSIs) 5.3.1 Global Surgical Site Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million) 5.4 Urinary Tract Infections (UTIs) 5.4.1 Global UTI Therapeutics Market Revenue, 2012 – 2020 (USD Million) 5.5 Gastrointestinal Disorders 5.5.1 Global Gastrointestinal Disorders Therapeutics Market Revenue, 2012 – 2020 (USD Million) 5.6 Bloodstream Infections 5.6.1 Global Bloodstream Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million) 5.7 Other Hospital Infections
Transparency Market Research
8
Hospital Infection Therapeutics Market
5.7.1 Global Other Hospital Infection Therapeutics Market Revenue, 2012 – 2020 (USD Million) Chapter 6 Hospital infection therapeutics Market, by Geography 6.1 Overview 6.1.1 Global Hospital infection therapeutics Market Revenue, by Geography, 2012 – 2020 (USD Million) 6.2 North America 6.2.1 North America Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million) 6.3 Europe 6.3.1 Europe Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million) 6.4 Asia Pacific 6.4.1 Asia Pacific Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million) 6.5 Rest of the World (RoW) 6.5.1 RoW Hospital infection therapeutics Market Revenue, 2012 - 2020 (USD Million) Chapter 7 Recommendations Chapter 8 Company Profiles 8.1 Actavis plc 8.1.1 Company Overview 8.1.2 Financial Overview 8.1.3 Product Portfolio 8.1.4 Business Strategies 8.1.5 Recent Developments
Transparency Market Research
9
Hospital Infection Therapeutics Market
8.2 AstraZeneca plc 8.2.1 Company Overview 8.2.2 Financial Overview 8.2.3 Product Portfolio 8.2.4 Business Strategies 8.2.5 Recent Developments 8.3 Bayer AG 8.3.1 Company Overview 8.3.2 Financial Overview 8.3.3 Product Portfolio 8.3.4 Business Strategies 8.3.5 Recent Developments 8.4 Bristol-Myers Squibb Company 8.4.1 Company Overview 8.4.2 Financial Overview 8.4.3 Product Portfolio 8.4.4 Business Strategies 8.4.5 Recent Developments 8.5 Cubist Pharmaceuticals, Inc. 8.5.1 Company Overview 8.5.2 Financial Overview
Transparency Market Research
10
Hospital Infection Therapeutics Market
8.5.3 Product Portfolio 8.5.4 Business Strategies 8.5.5 Recent Developments 8.6 GlaxoSmithKline plc 8.6.1 Company Overview 8.6.2 Financial Overview 8.6.3 Product Portfolio 8.6.4 Business Strategies 8.6.5 Recent Developments 8.7 Johnson & Johnson Services, Inc. 8.7.1 Company Overview 8.7.2 Financial Overview 8.7.3 Product Portfolio 8.7.4 Business Strategies 8.7.5 Recent Developments 8.8 Merck & Co., Inc. 8.8.1 Company Overview 8.8.2 Financial Overview 8.8.3 Product Portfolio 8.8.4 Business Strategies 8.8.5 Recent Developments
Transparency Market Research
11
Hospital Infection Therapeutics Market
8.9 Pfizer, Inc. 8.9.1 Company Overview 8.9.2 Financial Overview 8.9.3 Product Portfolio 8.9.4 Business Strategies 8.9.5 Recent Developments 8.10 Sanofi 8.10.1 Company Overview 8.10.2 Financial Overview 8.10.3 Product Portfolio 8.10.4 Business Strategies 8.10.5 Recent Developments Browse All Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html
About Us
Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forwardlooking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Transparency Market Research
12
Hospital Infection Therapeutics Market
Contact
Transparency Market Research 90 State Street, Suite 700, Albany NY - 12207 United States Tel: +1-518-618-1030 USA - Canada Toll Free 866-552-3453 Email: sales@transparencymarketresearch.com Website: http://www.transparencymarketresearch.com/ Browse The Market Research Blog : http://researchreportsindustry.wordpress.com/
Transparency Market Research
13